Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healios KK ( (JP:4593) ) has provided an update.
Healios K.K. has signed a letter of intent with Japanese pharmaceutical wholesaler Alfresa Corporation to establish a framework for the continuous sale and purchase of its human bone marrow-derived somatic stem cell culture supernatant, HLSI071. Building on an existing business alliance covering distribution and sales, the agreement is intended to secure stable, efficient nationwide distribution of the culture supernatant via Alfresa’s extensive network, enhancing timely delivery to customers. With the launch of its own manufacturing facility for culture supernatant, Healios will end earlier discussions on a potential manufacturing alliance with Alfresa group company Cell Resources, signaling a shift to in-house production while leveraging Alfresa for market access. The company stated that the arrangement is not expected to affect its consolidated financial results for the current fiscal year, but it strengthens its commercialization infrastructure in Japan’s regenerative medicine market.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen301.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. is a Japan-based clinical-stage biotechnology company focused on regenerative medicine, developing innovative therapies using somatic stem cells and induced pluripotent stem (iPS) cells. Its pipeline includes invimestrocel (HLCM051), a MAPC-based cell therapy targeting ischemic stroke, ARDS and trauma, and HLCN061, a gene-edited iPSC-derived NK cell therapy for solid tumors, supported by proprietary global platforms and scalable 3D bioreactor manufacturing. Listed on the Tokyo Stock Exchange’s Growth market, Healios aims to address severe unmet medical needs in immuno-oncology, ophthalmology, liver diseases and other areas through next-generation regenerative treatments.
Average Trading Volume: 3,234,137
Technical Sentiment Signal: Sell
Current Market Cap: Yen39.14B
For a thorough assessment of 4593 stock, go to TipRanks’ Stock Analysis page.